Subcutaneous Abatacept in Patients With Polyarticular ‐Course Juvenile Idiopathic Arthritis: Results From a Phase III Open‐Label Study

ConclusionWeight‐stratified SC abatacept yielded target therapeutic exposures across age and weight groups, was well tolerated, and improved pJIA symptoms over 24 months.This article is protected by copyright. All rights reserved.

Source: Arthritis and Rheumatism - February 26, 2018 Category: Rheumatology Authors: Hermine I Brunner, Nikolay Tzaribachev, Gabriel Vega ‐Cornejo, Ingrid Louw, Alberto Berman, Inmaculada Calvo Penadés, Jordi Antón, Francisco Ávila‐Zapata, Rubén Cuttica, Gerd Horneff, Ivan Foeldvari, Vladimir Keltsev, Daniel J Kingsbury, Diego Osc Tags: Full Length Source Type: research